Several mTOR inhibitors have been evaluated in clinical studies in osteosarcomas, including ridaforolimus [47], sirolimus [48], everolimus [38], and temsirolimus [49,50], either as a single-agent therapy or in combination with chemotherapy or other targeted therapies. This evidence concerns the gene MTOR and osteosarcoma.